AbbVie Inc. $ABBV Position Cut by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. decreased its position in AbbVie Inc. (NYSE:ABBV) by 95.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,000 shares of the company’s stock after selling 256,264 shares during the quarter. Jefferies Financial Group Inc.’s holdings in AbbVie were worth $3,139,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ABBV. Burk Holdings LLC acquired a new stake in shares of AbbVie during the second quarter worth $30,000. Marquette Asset Management LLC lifted its position in shares of AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after buying an additional 48 shares during the last quarter. Principia Wealth Advisory LLC lifted its position in shares of AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after buying an additional 44 shares during the last quarter. IMG Wealth Management Inc. boosted its holdings in shares of AbbVie by 3,060.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock valued at $40,000 after buying an additional 153 shares during the period. Finally, Tacita Capital Inc acquired a new position in shares of AbbVie in the 2nd quarter valued at about $42,000. 70.23% of the stock is currently owned by institutional investors.

Insider Activity

In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of the business’s stock in a transaction on Monday, November 9th. The shares were sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the sale, the executive vice president directly owned 83,171 shares of the company’s stock, valued at $24,419,005.60. The trade was a 32.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ABBV shares. Weiss Ratings upgraded shares of AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Cantor Fitzgerald lifted their target price on AbbVie from $290.00 to $325.00 and gave the company an “overweight” rating in a research note on Monday, November 2nd. Piper Sandler upped their target price on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Morgan Stanley increased their price target on AbbVie from $310.00 to $346.00 and gave the stock an “overweight” rating in a research report on Monday, November 2nd. Finally, The Goldman Sachs Group increased their price target on AbbVie from $258.00 to $294.00 and gave the stock a “neutral” rating in a research report on Friday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $297.46.

AbbVie Trading Down 0.1%

Shares of NYSE:ABBV opened at $294.75 on Friday. The company has a 50 day moving average of $274.82 and a 200-day moving average of $240.55. The firm has a market cap of $521.01 billion, a P/E ratio of 50.73, a P/E/G ratio of 1.34 and a beta of 0.20. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $302.93.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The company had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. During the same quarter in the previous year, the business earned $1.86 EPS. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. Equities research analysts forecast that AbbVie Inc. will post 13.98 EPS for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be issued a dividend of $1.82 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Friday, January 15th. AbbVie’s dividend payout ratio (DPR) is presently 119.10%.

Recent AbbVie Headlines

Investors following ABBV have been watching these headlines:

• Positive Sentiment: AbbVie recently raised its 2026 revenue guidance to about $67.8 billion and increased its dividend after reporting third-quarter revenue of $17.4 billion. These updates reinforce the company’s earnings and shareholder-return outlook. Can AbbVie Justify Its Valuation After Raised Guidance and Strong Results?
• Neutral Sentiment: A Crohn’s disease study update drew coverage describing its likely near-term stock impact as limited; it does not appear to materially change the immediate investment outlook. AbbVie Crohn’s Disease Study Update
• Negative Sentiment: Executive Vice President Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. Insider sales can weigh on sentiment, though the filing does not explain the reason for the transaction. SEC Form 4 filing

AbbVie Company Profile

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.